Affinia Therapeutics IPO

Affinia Therapeutics’ was founded in 2019 by Aaron Tward, Botond Roska, Luk Vandenberghe, Rob Aboud, and Robert Johnson. Affina Therapeutics has made an S-1 public filing.

Affinia Therapeutics’ purpose is to develop gene therapies that can have a transformative impact on people affected by devastating rare and non-rare diseases and methodically engineer novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields. Per Forge data, Affinia Therapeutics has raised a total of $170 million in funding over 2 rounds. Their latest funding was raised on May 3, 2021, from a Series B round. Key investors include Farallon Capital Management, F-Prime Capital, New Enterprise Associates, and EcoR1 Capital.

These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.

Register for Details

For more details on financing and valuation for Affinia Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Affinia Therapeutics

Forge green plus iconForge green minus icon

What is Affinia Therapeutics's IPO price?

The IPO price for Affinia Therapeutics will be known only if it becomes public. However, you may access the "Price At Last Round" and the "Implied EV" for publicly traded comparable companies with Forge Data.
Forge green plus iconForge green minus icon

Can you invest in Affinia Therapeutics?

Affinia Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Forge green plus iconForge green minus icon

Can you sell Affinia Therapeutics shares pre-IPO?

If you own Affinia Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.

Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.

Forge green plus iconForge green minus icon

Is Affinia Therapeutics a publicly traded company?

Affinia Therapeutics is a private company and not publicly traded.

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

Forge green plus iconForge green minus icon

What is Affinia Therapeutics's funding to date?

Affinia Therapeutics has raised $179.09MM to date.
Forge green plus iconForge green minus icon

When was Affinia Therapeutics founded?

Affinia Therapeutics was founded in 2019.

Affinia Therapeutics Funding Rounds and Last Known Valuation

Date Funding Round Funding Raised Price per Share Last Known Valuation
5/3/2021 Series B $110MM raised $XXX.XX $XXX.XX
3/31/2020 Series A $60.57MM raised $XXX.XX $XXX.XX
11/5/2019 Series A-1 $8.52MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.